Bessemer Group
XPH icon

Bessemer Group’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Bessemer Group’s Portfolio XPH Stock Details XPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-747
Closed -$30K – 1467
2016
Q1 		$30K Buy
+747
New +$31.6K ﹤0.01% 987

Other funds holding XPH

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return
KHLMVGHM
Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet Tel Aviv, Israel $2.44B AUM 24.95% 1-Year Est. Return
HCIA
Hochman Cole Investment Advisors Deerfield, Illinois $255M AUM 23.27% 1-Year Est. Return

Bessemer Group's XPH Position: Q2 2016 in Review

Bessemer Group sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q2 2016, closing a stake of 747 shares — an estimated $30K sold.

Bessemer Group first reported a position in XPH in Q1 2016 and held it in 1 quarter. The position peaked at $30K in Q1 2016. 60 funds tracked by Wall St. Rank hold XPH as of Q2 2016.

  • Bessemer Group reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q2 2016 after selling out during the quarter.
  • Bessemer Group sold 747 State Street SPDR S&P Pharmaceuticals ETF shares in Q2 2016, an estimated $30K.
  • Bessemer Group first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q1 2016 and held it in 1 quarter.
  • Bessemer Group's State Street SPDR S&P Pharmaceuticals ETF position peaked at $30K in Q1 2016.
  • 60 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q2 2016.

Based on Bessemer Group's 13F filing for Q2 2016, filed 11 Aug 2016.